Actinogen Medical
ASX:ACWSydney, Australia· Est.
Australian‑focused biotech advancing a brain‑cortisol inhibitor for Alzheimer’s and depression.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Australian‑focused biotech advancing a brain‑cortisol inhibitor for Alzheimer’s and depression.
NeurologyPsychiatry
Technology Platform
Selective oral inhibition of brain 11β‑HSD1 to lower intracellular cortisol, addressing neuro‑inflammation and cognitive decline.
Opportunities
Positive Phase 2b/3 data could unlock partnerships or acquisition, while expanding into depression and Fragile X offers a broader addressable market.
Risk Factors
Clinical failure or regulatory delays for Xanamem would severely impact valuation; reliance on a single asset and limited cash runway pose financial risk.
Competitive Landscape
Few companies target brain cortisol; Xanamem differentiates from amyloid/tau‑focused AD therapies and from conventional antidepressants, but must compete with other 11β‑HSD1 inhibitors and emerging disease‑modifying agents.